Author

Emma L. Turner

University of BristolORCID 0000-0003-2575-387XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 3 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:polygenic risk· 3 Approach:statistical model· 3 Assay:GWAS summary statistics· 2 Assay:whole-exome sequencing· 2 Research Focus:differential expression· 1 Approach:machine learning (classical)· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Adam Stuart KibeliD· 4 shared Anders Martin DaleiD· 4 shared Cezary CybulskiiD· 4 shared David Edgar NealiD· 4 shared Freddie Charles HamdyiD· 4 shared Fredrik E. WiklundiD· 4 shared Ian Geoffrey MillsiD· 4 shared Jenny DonovaniD· 4 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersGenetic & Genomic Medicine

Adam Stuart KibelORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Germline polygenic score for prostate cancer aggressiveness

George Jing Xu, Roshan A. Karunamuni, Anna M. Dornisch, Charles A. Brunette, Morgan E. Danowski, Heena Desai, Daniel R. Dochtermann, Isla P. Garraway, Richard L. Hauger, Adam Stuart Kibel, Julie Ann Lynch, Saiju Pyarajan, Brent Shane Rose, Craig Carl Teerlink, Ole A. Andreassen, , Tyler M. Seibert

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

medRxiv · May 13, 2026 · PreprintGenetic & Genomic Medicine

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

Jason L. Vassy, Anna M. Dornisch, Roshan A. Karunamuni, Michael Gatzen, C. Kachulis, Niall J. Lennon, Charles A. Brunette, Morgan E. Danowski, Richard L. Hauger, Isla P. Garraway, Adam Stuart Kibel, Kyung Min Lee, Julie Ann Lynch, Kara N. Maxwell, Brent Shane Rose, , Tyler M. Seibert

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

medRxiv · Nov 3, 2024 · PreprintGenetic & Genomic Medicine

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

UKGPCS collaborators, Roshan A. Karunamuni, APCB BioResource (Australian Prostate Cancer BioResource), Canary PASS Investigators, Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Wesley Kurt Thompson, Rosalind A. Eeles, Zsofia Kote‐Jarai, Kenneth Ross Muir, Artitaya Lophatananon, Johanna Schleutker, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, , Tyler M. Seibert

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.

Prostate Cancer and Prostatic Diseases · Jan 8, 2021Peer-reviewedGenetic & Genomic Medicine

A genetic hazard score to personalize prostate cancer screening, applied to population data

Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Roshan A. Karunamuni, Eleanor I. Walsh, Emma L. Turner, J. Athene Lane, Richard Michael Martin, David Edgar Neal, Jenny Donovan, Freddie Charles Hamdy, John Kellogg Parsons, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, , Tyler M. Seibert

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

bioRxiv · Apr 26, 2019 · PreprintGenetics